ARSL

Across TCGA pan-cancer cohorts, ARSL RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of ARSL’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARSL RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARSL is over-expressed in tumor, although a few such as LUSC and UCEC show the opposite, repressed pattern.

KIRC, HNSC, and STAD are the cancer types where ARSL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARSL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	IV	+1.600	<.001	12	view →
HNSC	All	III,IV	+0.764	<.001	12	view →
STAD	All	II,III,IV	+2.239	<.001	7	view →
LUAD	Male	II,III,IV	+1.916	<.001	7	view →
THCA	All	All	+0.359	<.001	6	view →
BRCA	All	All	+0.333	.004	6	view →
LUSC	Female	All	−1.117	<.001	5	view →
COAD	All	All	+0.989	<.001	5	view →
READ	Female	All	+1.407	.016	3	view →
UCEC	All	IV	−2.795	.022	2	view →
CHOL	All	All	−1.400	.012	2	view →
LIHC	Male	II,III,IV	+0.636	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

ARSL–KIRC

Open the KIRC breakdown →